Kliogest (Norethisterone Acetate, Estradiol)

Norethisterone acetate (a progestogen) and estradiol (an estrogen) work together to suppress the hypothalamic‑pituitary‑ovarian axis, lowering LH and FSH release and preventing ovulation. The progestogen also thickens cervical mucus and alters the endometrium, while the estrogen stabilises the uterine lining, creating multiple barriers to fertilisation and implantation.

The dosage of Kliogest is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet following a specific regimen, but the exact schedule and number of tablets per cycle should be individualized by the prescriber based on patient needs.

Kliogest is classified as Pregnancy Category X, meaning it must not be used during pregnancy because it can harm the fetus. It is also not recommended for breastfeeding women, as hormonal components may pass into breast milk and affect the infant.

To order Kliogest, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kliogest contains norethisterone acetate and estradiol, a formulation similar to other estrogen‑progestogen pills but with a specific estrogen dose that may offer a different bleeding profile. Compared with pills containing ethinyl estradiol, estradiol may have a more natural metabolic pathway, though efficacy and safety remain comparable when used correctly.

Kliogest tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain tablet integrity.

Kliogest is taken orally, usually once daily at the same time each day. Patients should swallow the tablet whole with water and follow the specific cycle regimen prescribed by their healthcare provider, which may include a placebo or hormone‑free interval.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial events such as stroke or myocardial infarction, and rare hepatic tumors. Women with a history of clotting disorders, smoking over age 35, or uncontrolled hypertension are at higher risk.

Kliogest should not be used by women who are pregnant, have known or suspected breast cancer, have a history of thromboembolic disease, uncontrolled hypertension, severe liver disease, or are smokers over 35 years of age. It is also contraindicated in individuals with known hypersensitivity to any component of the tablet.